LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Plasma Lipids Associated Differently with Dementia Incidents

By LabMedica International staff writers
Posted on 12 Apr 2017
Print article
Image: The cumulative incidence of dementia according to lipid concentrations (triglycerides, HDL-C, LDL-C, total cholesterol) (Photo courtesy of the University of Bordeaux).
Image: The cumulative incidence of dementia according to lipid concentrations (triglycerides, HDL-C, LDL-C, total cholesterol) (Photo courtesy of the University of Bordeaux).
Dementia refers to a group of neurological disorders characterized by memory loss, cognitive impairment, and disability in activities of daily living. As the primary risk factor for dementia is old age, the prevalence of dementia is increasing dramatically with aging populations worldwide.

Vascular risk factors have been proposed as important targets for the prevention of dementia, with around a third of Alzheimer disease (AD) cases being attributable to potentially modifiable risk factors, especially vascular risk factors although trials have been inconclusive so far. As lipid fractions represent easily modifiable potential targets for prevention, exploring their relation with dementia risk is of major interest.

Scientists at the University of Bordeaux and their colleagues recruited 9,294 non-institutionalized persons aged 65 years and over were recruited from the electoral rolls of Dijon, Bordeaux, and Montpellier, France, between March 1999 and March 2001. Extensive follow-up examinations were performed every two years after the baseline assessment, comprising standardized questionnaires, clinical examinations, and detailed cognitive assessment. The final study sample comprised 7,470 participants from the study, mean age ± standard deviation (SD), 73.8 ± 5.3 years, and 61.0% were women, who were prospectively followed up for up to 13 years.

Fasting lipid fractions (triglycerides [TGs], high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], and total cholesterol [TC]) were studied as continuous variables, and results are reported per SD increase of each lipid fraction. Analyses were adjusted for sex, study center, and educational level, as well as vascular risk factors and apolipoprotein E (APOE) ε4 genotype. Centralized measurements of baseline fasting serum TC, HDL-C, and TG were performed using enzymatic methods. LDL-C was calculated with the Friedewald formula and was considered missing for TG values greater than 400 mg/dL (4.52 mmol/L).

The team reported that 779 participants developed incident dementia 532 with AD and 154 with mixed or vascular dementia. Higher LDL-C and TC concentrations at baseline were associated with an increased risk of AD. These associations were largely unchanged after adjustment for vascular risk factors and were attenuated after adjustment for APOEε4. Higher TG concentrations at baseline were associated with an increased risk of all and mixed or vascular dementia, however, these associations disappeared after adjusting for vascular risk factors.

The authors concluded that higher LDL-C and TC concentrations were associated with an increased risk of AD. This result was independent of vascular risk factors and was attenuated after adjustment for APOEε4 carrier status. TG and HDL-C concentrations were not associated with risk of incident dementia or its subtypes after accounting for vascular risk factors. The study was published on March 28, 2017, in the journal Public Library of Science Medicine.

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
New
Myeloperoxidase Assay
IDK MPO ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.